Neurvati Neurosciences/GRIN Therapeutics issued a press release announcing that the European Medicines Agency (EMA) has granted Priority Medicine (PRIME) designation to radiprodil, the company’s investigational, potent negative allosteric modulator selectively targeting the GluN2B (or NR2B) subunit of the N-methyl-D-aspartate receptor ), for the treatment of GRIN-related neurodevelopmental disorder (NDD). PRIME designation is granted by the EMA in recognition of priority medicines that have demonstrated the potential to target an unmet need to a significant extent. PRIME provides enhanced support for the development of therapeutic candidates in order to help optimize development plans and speed up the evaluation process. You can find the press release here: https://lnkd.in/dWanJnBs... #grigenedisorders #gria #grid #grik #grin
About us
GRI-UK helps people with GRIA, GRID, GRIK and GRIN gene disorders by: aiming to advance cures and treatments; supporting families to lead the best life possible; raising awareness of the symptoms and needs of people with GRI disorders, to help enable better and faster access to diagnosis and treatments; and bringing together patients, parents, family members, medical professionals, researchers, scientists, pharmaceutical, bioscience and academic communities.
- Website
-
www.gri-uk.org
External link for GRI-UK
- Industry
- Non-profit Organizations
- Company size
- 1 employee
- Headquarters
- London
- Type
- Nonprofit
- Founded
- 2024
Locations
-
Primary
Get directions
London, GB
Employees at GRI-UK
Updates
-
Reminder of our next GRI Connect Catch Up's is Tuesday, 8th April. Everyone welcome, ZOOM link will be sent out day before. For a Zoom Link or more information please PM or Email: info@gri-uk.org #grigenedisorders #gria #grid #grik #grin
-